Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors.

Holscher CM, Haugen CE, Jackson KR, Garonzik Wang JM, Waldram MM, Bae S, Locke JE, Reed RD, Lentine KL, Gupta G, Weir MR, Friedewald JJ, Verbesey J, Cooper M, Segev DL, Massie AB.

Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1493-1499. doi: 10.2215/CJN.04020419. Epub 2019 Sep 19.

PMID:
31537534
2.

Impact of donor hepatitis C virus on kidney transplant outcomes for hepatitis C positive recipients in the direct acting antiviral era: time to revise the kidney donor risk index?

Cannon RM, Locke JE, Orandi BJ, Anderson DJ, Davis EG, Mackelaite L, Dave H, Eng M, Jones CM.

Transplantation. 2019 Sep 9. doi: 10.1097/TP.0000000000002949. [Epub ahead of print]

PMID:
31517783
3.

Donation approval among obese living kidney donor candidates: The impact of metabolic syndrome.

Mustian MN, Kumar V, Hanaway M, MacLennan PA, Shelton BA, Reed RD, Correya T, Grant R, Carter A, Baker G, Patterson J, Peoples M, Holden S, Orandi BJ, Locke JE.

Surgery. 2019 Nov;166(5):940-946. doi: 10.1016/j.surg.2019.07.008. Epub 2019 Aug 20.

PMID:
31444005
4.

Mitigating Racial and Sex Disparities in Access to Living Donor Kidney Transplantation: Impact of the Nation's Longest Single-center Kidney Chain.

Mustian MN, Kumar V, Stegner K, Mompoint-Williams D, Hanaway M, Deierhoi MH, Young C, Orandi BJ, Anderson D, MacLennan PA, Reed RD, Shelton BA, Eckhoff D, Locke JE.

Ann Surg. 2019 Oct;270(4):639-646. doi: 10.1097/SLA.0000000000003484.

PMID:
31348035
5.

Patient Perspectives on Weight Management for Living Kidney Donation.

Mustian MN, Hanaway M, Kumar V, Reed RD, Shelton BA, Grant R, Carter A, Locke JE.

J Surg Res. 2019 Jul 3;244:50-56. doi: 10.1016/j.jss.2019.06.026. [Epub ahead of print]

PMID:
31279263
6.

Center Variation and Risk Factors for Failure to Complete 6 Month Postdonation Follow-up Among Obese Living Kidney Donors.

Reed RD, MacLennan PA, Shelton BA, Mustian MN, Blackburn J, Smith SC, Terry KB, Grant R, Sawinski D, Locke JE.

Transplantation. 2019 Jul;103(7):1450-1456. doi: 10.1097/TP.0000000000002508.

PMID:
31241556
7.

CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.

Yanik MV, Seifert ME, Locke JE, Hauptfeld-Dolejsek V, Crowley MR, Cutter GR, Mannon RB, Feig DI, Limdi NA.

Pediatr Transplant. 2019 Aug;23(5):e13494. doi: 10.1111/petr.13494. Epub 2019 May 24.

PMID:
31124575
8.

Get on with it!-A novel allocation strategy to reduce kidney discards.

Locke JE, Sellers MT.

Am J Transplant. 2019 May 23. doi: 10.1111/ajt.15471. [Epub ahead of print] No abstract available.

PMID:
31119845
9.

Obesity and long-term mortality risk among living kidney donors.

Locke JE, Reed RD, Massie AB, MacLennan PA, Sawinski D, Kumar V, Snyder JJ, Carter AJ, Shelton BA, Mustian MN, Lewis CE, Segev DL.

Surgery. 2019 Aug;166(2):205-208. doi: 10.1016/j.surg.2019.03.016. Epub 2019 May 7.

PMID:
31072668
10.

Time for reform in transplant program-specific reporting: AST/ASTS transplant metrics taskforce.

Chandraker A, Andreoni KA, Gaston RS, Gill J, Locke JE, Mathur AK, Norman DJ, Patzer RE, Rana A, Ratner LE, Schold JD, Pruett TL; AST/ASTS Transplant Metrics Taskforce.

Am J Transplant. 2019 Jul;19(7):1888-1895. doi: 10.1111/ajt.15394. Epub 2019 May 23.

PMID:
31012525
11.

Enhanced Advocacy and Health Systems Training through Patient Navigation Increases Access to Living Donor Kidney Transplantation.

Locke JE, Reed RD, Kumar V, Berry B, Hendricks D, Carter A, Shelton BA, Mustian MN, MacLennan PA, Qu H, Hannon L, Yates C, Hanaway MJ.

Transplantation. 2019 Apr 1. doi: 10.1097/TP.0000000000002732. [Epub ahead of print]

PMID:
30946213
12.

Kidney Transplantation in a HIV-Positive Recipient.

Sawinski D, Locke JE.

Clin J Am Soc Nephrol. 2019 Apr 5;14(4):614-616. doi: 10.2215/CJN.14051118. Epub 2019 Mar 18. No abstract available.

PMID:
30885910
13.

Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.

Sawinski D, Forde KA, Lo Re V 3rd, Goldberg DS, Cohen JB, Locke JE, Bloom RD, Brensinger C, Weldon J, Shults J, Reese PP.

Am J Kidney Dis. 2019 Jun;73(6):815-826. doi: 10.1053/j.ajkd.2018.11.009. Epub 2019 Jan 29.

PMID:
30704882
14.

Patient-reported outcome measures for life participation in kidney transplantation: A systematic review.

Ju A, Chow BY, Ralph AF, Howell M, Josephson MA, Ahn C, Butt Z, Dobbels F, Fowler K, Jowsey-Gregoire S, Jha V, Locke JE, Tan JC, Taylor Q, Rutherford C, Craig JC, Tong A.

Am J Transplant. 2019 Aug;19(8):2306-2317. doi: 10.1111/ajt.15267. Epub 2019 Feb 28.

PMID:
30664327
15.

Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: Pre- vs posttransplant.

Shelton BA, Berdahl G, Sawinski D, Linas BP, Reese PP, Mustian MN, Reed RD, MacLennan PA, Locke JE.

Am J Transplant. 2019 Jun;19(6):1806-1819. doi: 10.1111/ajt.15239. Epub 2019 Jan 25.

PMID:
30589503
16.

Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus.

Cohen JB, Locke JE, Shelton B, Reed RD, Mustian M, MacLennan P, Forde KA, Reese PP, Sawinski D.

Clin Transplant. 2019 Feb;33(2):e13466. doi: 10.1111/ctr.13466. Epub 2019 Jan 12.

PMID:
30578590
17.

Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates.

Mustian MN, Shelton BA, MacLennan PA, Reed RD, White JA, Eckhoff DE, Locke JE, Allman RM, Gray SH.

Transplantation. 2019 Jul;103(7):1425-1432. doi: 10.1097/TP.0000000000002523.

PMID:
30418427
18.

Can you hear me now? Patient preferences for evaluating kidney transplant centers.

Sawinski D, Locke JE.

Am J Transplant. 2018 Nov;18(11):2624. doi: 10.1111/ajt.15066. Epub 2018 Sep 4. No abstract available.

PMID:
30091840
19.

Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation.

Shelton BA, Sawinski D, Linas BP, Reese PP, Mustian M, Hungerpiller M, Reed RD, MacLennan PA, Locke JE.

Am J Transplant. 2018 Oct;18(10):2483-2495. doi: 10.1111/ajt.15040. Epub 2018 Aug 30.

20.

Expand the Pool of Living Donors for Kidney Transplantation.

Locke JE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1142-1143. doi: 10.2215/CJN.07310618. Epub 2018 Jul 16. No abstract available.

21.

Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation.

Reed RD, Sawinski D, Shelton BA, MacLennan PA, Hanaway M, Kumar V, Long D, Gaston RS, Kilgore ML, Julian BA, Lewis CE, Locke JE.

Transplantation. 2018 Dec;102(12):2080-2087. doi: 10.1097/TP.0000000000002286.

PMID:
29787519
22.

Redefining the Influence of Ethnicity on Simultaneous Kidney and Pancreas Transplantation Outcomes: A 15-Year Single-Center Experience.

Young CJ, MacLennan PA, Mannon EC, Reed RD, Shelton BA, Hanaway MJ, Agarwal G, Gaston RS, Julian BA, Kew CE 2nd, Kumar V, Mannon RB, Mehta S, Ong SC, Towns GC, Deierhoi MH, Locke JE.

Ann Surg. 2018 May 17. doi: 10.1097/SLA.0000000000002816. [Epub ahead of print]

PMID:
29781845
23.

Response to "It is time to revise the kidney allocation system to restore the pediatric advantage".

Shelton BA, Locke JE.

Am J Transplant. 2018 Sep;18(9):2367. doi: 10.1111/ajt.14934. Epub 2018 Jun 11. No abstract available.

24.

In Reply to 'Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline'.

Sawinski D, Locke JE.

Am J Kidney Dis. 2018 Jul;72(1):155. doi: 10.1053/j.ajkd.2018.02.359. Epub 2018 Apr 16. No abstract available.

PMID:
29673727
25.

Impact of the new kidney allocation system A2/A2B → B policy on access to transplantation among minority candidates.

Martins PN, Mustian MN, MacLennan PA, Ortiz JA, Akoad M, Caicedo JC, Echeverri GJ, Gray SH, Lopez-Soler RI, Gunasekaran G, Kelly B, Mobley CM, Black SM, Esquivel C, Locke JE.

Am J Transplant. 2018 Aug;18(8):1947-1953. doi: 10.1111/ajt.14719. Epub 2018 Mar 31.

26.

Response to: Regarding "HIV protease inhibitors and mortality following kidney transplantation".

Shelton BA, Sawinski D, Locke JE.

Am J Transplant. 2018 Jun;18(6):1571. doi: 10.1111/ajt.14688. Epub 2018 Mar 5. No abstract available.

27.

Evaluation of Kidney Donors: Core Curriculum 2018.

Sawinski D, Locke JE.

Am J Kidney Dis. 2018 May;71(5):737-747. doi: 10.1053/j.ajkd.2017.10.018. Epub 2018 Jan 11. Review.

28.

Decreasing deceased donor transplant rates among children (≤6 years) under the new kidney allocation system.

Shelton BA, Sawinski D, Ray C, Reed RD, MacLennan PA, Blackburn J, Young CJ, Gray S, Yanik M, Massie A, Segev DL, Locke JE.

Am J Transplant. 2018 Jul;18(7):1690-1698. doi: 10.1111/ajt.14663. Epub 2018 Feb 7.

29.

Expanding clarity or confusion? Volatility of the 5-tier ratings assessing quality of transplant centers in the United States.

Schold JD, Andreoni KA, Chandraker AK, Gaston RS, Locke JE, Mathur AK, Pruett TL, Rana A, Ratner LE, Buccini LD.

Am J Transplant. 2018 Jun;18(6):1494-1501. doi: 10.1111/ajt.14659. Epub 2018 Feb 9.

30.

Landscape of ABO-Incompatible Live Donor Kidney Transplantation in the US.

Mustian MN, Cannon RM, MacLennan PA, Reed RD, Shelton BA, McWilliams DM, Deierhoi MH, Locke JE.

J Am Coll Surg. 2018 Apr;226(4):615-621. doi: 10.1016/j.jamcollsurg.2017.12.026. Epub 2018 Jan 5.

31.

Assessing emergency department utilization in the era of population health.

Schold JD, Locke JE.

Am J Transplant. 2018 Apr;18(4):777-778. doi: 10.1111/ajt.14641. Epub 2018 Jan 21. No abstract available.

32.

Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney.

Shelton BA, Sawinski D, Mehta S, Reed RD, MacLennan PA, Locke JE.

Transpl Infect Dis. 2018 Apr;20(2):e12829. doi: 10.1111/tid.12829. Epub 2018 Jan 25.

PMID:
29277956
33.

Apolipoprotein L1 Gene Effects on Kidney Transplantation.

Freedman BI, Locke JE, Reeves-Daniel AM, Julian BA.

Semin Nephrol. 2017 Nov;37(6):530-537. doi: 10.1016/j.semnephrol.2017.07.006. Review.

34.

Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice.

Sawinski D, Forde KA, Locke JE, Cohen JB, Weldon J, Shults J, Reese PP.

Kidney Int. 2018 Mar;93(3):706-715. doi: 10.1016/j.kint.2017.08.015. Epub 2017 Oct 26.

PMID:
29107361
35.

Expanding the use of hepatitis C-viremic kidney donors.

Sawinski D, Wyatt CM, Locke JE.

Kidney Int. 2017 Nov;92(5):1031-1033. doi: 10.1016/j.kint.2017.09.002.

PMID:
29055420
36.

Urologic malignancies in kidney transplantation.

Hickman LA, Sawinski D, Guzzo T, Locke JE.

Am J Transplant. 2018 Jan;18(1):13-22. doi: 10.1111/ajt.14533. Epub 2017 Dec 1. Review.

37.

Long Cold Ischemia Times in Same Hospital Deceased Donor Transplants.

Chow EK, DiBrito S, Luo X, Wickliffe CE, Massie AB, Locke JE, Gentry SE, Garonzik-Wang J, Segev DL.

Transplantation. 2018 Mar;102(3):471-477. doi: 10.1097/TP.0000000000001957.

38.

Patient and Kidney Allograft Survival in Recipients With End-Stage Renal Disease From Amyloidosis.

Sawinski D, Lim MA, Cohen JB, Locke JE, Weiss B, Hogan JJ, Dember LM.

Transplantation. 2018 Feb;102(2):300-309. doi: 10.1097/TP.0000000000001930.

PMID:
28885498
39.

Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes.

Cohen JB, Eddinger KC, Shelton B, Locke JE, Forde KA, Sawinski D.

Clin Kidney J. 2017 Aug;10(4):564-572. doi: 10.1093/ckj/sfx048. Epub 2017 Jul 11.

40.

Living Kidney Donor Phenotype and Likelihood of Postdonation Follow-up.

Reed RD, Shelton BA, MacLennan PA, Sawinski DL, Locke JE.

Transplantation. 2018 Jan;102(1):135-139. doi: 10.1097/TP.0000000000001881.

41.

PROviding Better ACcess To ORgans: A comprehensive overview of organ-access initiatives from the ASTS PROACTOR Task Force.

Hobeika MJ, Miller CM, Pruett TL, Gifford KA, Locke JE, Cameron AM, Englesbe MJ, Kuhr CS, Magliocca JF, McCune KR, Mekeel KL, Pelletier SJ, Singer AL, Segev DL.

Am J Transplant. 2017 Oct;17(10):2546-2558. doi: 10.1111/ajt.14441. Epub 2017 Sep 2.

42.

Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients.

Sawinski D, Shelton BA, Mehta S, Reed RD, MacLennan PA, Gustafson S, Segev DL, Locke JE.

Am J Transplant. 2017 Dec;17(12):3114-3122. doi: 10.1111/ajt.14419. Epub 2017 Aug 24.

43.

Survival Benefit of Transplantation with a Deceased Diabetic Donor Kidney Compared with Remaining on the Waitlist.

Cohen JB, Eddinger KC, Locke JE, Forde KA, Reese PP, Sawinski DL.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):974-982. doi: 10.2215/CJN.10280916. Epub 2017 May 25.

44.

Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors.

Muzaale AD, Althoff KN, Sperati CJ, Abraham AG, Kucirka LM, Massie AB, Kitahata MM, Horberg MA, Justice AC, Fischer MJ, Silverberg MJ, Butt AA, Boswell SL, Rachlis AR, Mayor AM, Gill MJ, Eron JJ, Napravnik S, Drozd DR, Martin JN, Bosch RJ, Durand CM, Locke JE, Moore RD, Lucas GM, Segev DL.

Am J Transplant. 2017 Jul;17(7):1823-1832. doi: 10.1111/ajt.14235. Epub 2017 May 12.

45.

Patterns of primary care utilization before and after living kidney donation.

Alejo JL, Luo X, Massie AB, Henderson ML, DiBrito SR, Locke JE, Purnell TS, Boyarsky BJ, Anjum S, Halpern SE, Segev DL.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12992. Epub 2017 Jun 5.

46.

Quantifying Postdonation Risk of ESRD in Living Kidney Donors.

Massie AB, Muzaale AD, Luo X, Chow EKH, Locke JE, Nguyen AQ, Henderson ML, Snyder JJ, Segev DL.

J Am Soc Nephrol. 2017 Sep;28(9):2749-2755. doi: 10.1681/ASN.2016101084. Epub 2017 Apr 27.

47.

The Authors Reply.

Locke JE, Reed RD, Massie AB, Segev DL.

Kidney Int. 2017 May;91(5):1256. doi: 10.1016/j.kint.2017.02.007. No abstract available.

PMID:
28407878
48.

Access to Kidney Transplantation among HIV-Infected Waitlist Candidates.

Locke JE, Mehta S, Sawinski D, Gustafson S, Shelton BA, Reed RD, MacLennan P, Bolch C, Durand C, Massie A, Mannon RB, Gaston R, Saag M, Overton T, Segev DL.

Clin J Am Soc Nephrol. 2017 Mar 7;12(3):467-475. doi: 10.2215/CJN.07460716. Epub 2017 Feb 23.

49.

Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors.

Locke JE, Sawinski D, Reed RD, Shelton B, MacLennan PA, Kumar V, Mehta S, Mannon RB, Gaston R, Julian BA, Carr JJ, Terry JG, Kilgore M, Massie AB, Segev DL, Lewis CE.

Ann Surg. 2018 Jun;267(6):1161-1168. doi: 10.1097/SLA.0000000000002174.

50.

Abdominal lean muscle is associated with lower mortality among kidney waitlist candidates.

Locke JE, Carr JJ, Nair S, Terry JG, Reed RD, Smith GD, Segev DL, Kumar V, Lewis CE.

Clin Transplant. 2017 Mar;31(3). doi: 10.1111/ctr.12911. Epub 2017 Feb 8.

Supplemental Content

Loading ...
Support Center